Summit begins enrolment for Phase II PhaseOut DMD trial of ezutromid to treat DMD

UK-based clinical-stage drug discovery and development company Summit Therapeutics has begun enrolment in the US for its Phase II PhaseOut DMD clinical trial of ezutromid to treat Duchenne muscular dystrophy (DMD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news